Use of E-cadherin and CD44 aids in the differentiation between reactive mesothelial cells and carcinoma cells in pelvic washings

Cancer

Volumn 90, Issue 5, 2000, Pages 299-306

  Chhieng, David C ^a   Yee, Herman ^b   Cangiarella, Joan F ^b   Symmans, W Fraser ^c   Cohen, Jean Marc ^d  

^a University of Alabama at Birmingham   (United States)

^b NEW YORK UNIVERSITY   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d BETH ISRAEL MEDICAL CENTER   (United States)

Author keywords

Adenocarcinoma; CD44; E cadherin; Immunocytochemistry; Mesothelial cells; Pelvic washings

Indexed keywords

HERMES ANTIGEN; UVOMORULIN;

ARTICLE; CELL DIFFERENTIATION; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DOUBLE BLIND PROCEDURE; FEMALE; GYNECOLOGIC CANCER; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MESOTHELIUM CELL; PERITONEUM LAVAGE; PRIORITY JOURNAL; PROTEIN ISOLATION;

ADENOCARCINOMA; ANTIGENS, CD44; CADHERINS; DIAGNOSIS, DIFFERENTIAL; EPITHELIAL CELLS; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; OVARIAN NEOPLASMS; PERITONEAL CAVITY; PERITONEAL NEOPLASMS; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 0034715666     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20001025)90:5<299::AID-CNCR6>3.0.CO;2-Z     Document Type: Article

References (62)

1. Prognostic value of cytologic peritoneal washings
2. The prognostic value of peritoneal cytology in gynecologic malignant disease
3. The significance of Mullerian inclusions found at second-look laparotomy in patients with epithelial ovarian neoplasms
4. Peritoneal washing cytology. Uses and diagnostic criteria in gynecologic neoplasms
5. Microscopic disease at second-look laparotomy in advanced ovarian cancer
6. Peritoneal washings in ovarian tumors. Potential sources of error in cytologic diagnosis
7. Misstaging of ovarian cancer
8. Cytology of peritoneal washings in gynecologic patients. Diagnostic criteria and pitfalls
9. Peritoneal cytology as an indicator of disease in patients with residual ovarian carcinoma
10. Multiple peritoneal cytologies collected during laparotomy for gynecologic malignancy
11. Experience with peritoneal cytology in the management of gynecologic malignancies
12. Peritoneal cytology in endometrial cancer: A review
13. Peritoneal washing cytology in women: Diagnostic pitfalls and clues for correct diagnosis
14. Cytology of peritoneal aspirates and washings
15. The distinction of adenocarcinoma from malignant mesothelioma in cell blocks of effusions: The role of routine mucin histochemistry and immunohistochemical assessment of carcinoembryonic antigen, keratin proteins, epithelial membrane antigen, and milk fat globule-derived antigen
16. Value of immunocytochemistry in the study of malignant effusion
17. The use of immunoperoxidase panels for the cytologic diagnosis of malignancy in serous effusions
18. Immunocytochemical profile of benign and carcinomatous effusions. A tactical approach to difficult diagnosis
19. Distinction between carcinoma cells and mesothelial cells in serous effusions. Usefulness of immunohistochemistry
20. Immunocytochemical panel for the identification of malignant cells in serous effusions
21. Immunocytochemistry in the differential diagnosis of effusions: Use of logistic regression to select a panel of antibodies to distinguish adenocarcinomas from mesothelial proliferations
22. Markers for metastatic adenocarcinoma in serous effusion specimens
23. Monoclonal antibody Ber-EP4: Its use in the differential diagnosis of malignant mesothelioma and carcinoma in cell blocks of malignant effusions and FNA specimens
24. Immunocytochemical staining of smears and corresponding cell blocks from serous effusions: A follow-up and comparative investigation
25. Ber-EP4 for differentiating adenocarcinoma from reactive and neoplastic mesothelial cells in serous effusions. Comparison with carcinoembryonic antigen, B72.3 and Leu-M1
26. Complementary value of five carcinoma markers for the diagnosis of malignant mesothelioma, adenocarcinoma metastasis, and reactive mesothelium in serous effusions
27. The differential expression of N-cadherin and E-cadherin distinguishes pleural mesotheliomas from lung adenocarcinomas
28. CD44H expression in reactive mesothelium, pleural mesothelioma and pulmonary adenocarcinoma
29. The cell adhesion molecule, E-cadherin, distinguishes mesothelial cells from carcinoma cells in fluids
30. Hyaluronate binding probe and CD44 in the differential diagnosis of malignant effusions: Disappointing results in cytology material
31. E-cadherin and calretinin: A useful combination of immunochemical markers for differentiation between mesothelioma and metastatic adenocarcinoma
32. E-cadherin, N-cadherin, and calretinin in pleural effusions: The good, the bad, the worthless
33. CD44 is the principal cell surface receptor for hyaluronate
34. A lymphocyte molecule implicated in lymph node homing is a member of the cartilage link protein family
35. CD44 and its interactions with extracellular matrix
36. Identification and purification of a cell surface glycoprotein mediating intercellular adhesion in embryonic and adult tissue
37. The body language of cells: The intimate connection between cell adhesion and behavior
38. Expression of cadherins and alpha-catenin in primary epithelial tumors of the liver
39. Expression of E-cadherin cell adhesion molecules in human breast cancer tissues and its relationship to metastasis
40. Selective expression of CD44 cell-adhesion molecule in thyroid papillary carcinoma fine-needle aspirates
41. Expression of cadherins in benign, borderline, and malignant ovarian epithelial tumors: A clinicopathologic study of 60 cases
42. Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons
43. Deranged activity of the CD44 gene and other loci as biomarkers for progression to metastatic malignancy
44. Binding and degradation of hyaluronan by human breast cancer cell lines expressing different forms of CD44: Correlation with invasive potential
45. Ligand binding specificity of alternatively spliced CD44 isoforms. Recognition and binding of hyaluronan by CD44R1
46. Stimulatory effects of pleural fluids from mesothelioma patients on CD44 expression, hyaluronan production and cell proliferation in primary cultures of normal mesothelial and transformed cells
47. Analysis of CD44 expression in serous and mucinous borderline tumors of the ovary: Comparison with cystadenomas and overt carcinomas
48. CD44 is not involved in the metastatic spread of ovarian cancer in vivo
49. Binding of ovarian cancer cells to peritoneal mesothelium in vitro is partly mediated by CD44H
50. Increased hyaluronan at sites of attachment to mesentery by CD44-positive mouse ovarian and breast tumor cells
51. Increased E-cadherin expression in ovarian surface epithelium: An early step in metaplasia and dysplasia?
52. E-cadherin expression in human epithelial ovarian cancer and normal ovary
53. Expression of E-cadherin, α-catenin and β-catenin in normal ovarian surface epithelium and epithelial ovarian cancers
54. Characterization of ovarian dysplasia by interactive morphometry
55. Early de novo ovarian carcinoma. A study of fourteen cases
56. p53 Protein expression in putative precursor lesions of epithelial ovarian cancer
57. Early de novo ovarian cancer and cancer developing in benign ovarian ovarian lesions
58. Unstable expression of E-cadherin expression adhesion molecules in metastatic ovarian tumor cells
59. Expression of E cadherin in normal, benign and malignant tissues of female genital organs
60. Florid mesothelial hyperplasia associated with ovarian tumors: A potential source of error in tumor diagnosis and staging